HLB Innovation's U.S. subsidiary, Verismo Therapeutics, has reported promising preclinical results for their solid tumor CAR-T therapy, SynKIR-110. The treatment showed enhanced anti-tumor activity compared to conventional single-chain CAR-T therapies, while reducing cytokine release, T cell exhaustion, and off-target effects.

Verismo announced on Wednesday that the abstract detailing SynKIR-110's preclinical study has been released. The findings will be presented as a poster at the Society for Immunotherapy of Cancer (SITC 2026) conference, scheduled for November 4-8 in Phoenix, Arizona.

This study directly compared SynKIR-110 with existing CD28 and 4-1BB-based single-chain CAR-T therapies to assess the unique properties of the KIR-CAR structure.

CAR-T therapy is a cutting-edge treatment that involves genetically modifying a patient's T cells to target and attack specific cancer cell antigens.

The published abstract reveals that SynKIR-110 achieved the fastest tumor control while maintaining lower cytokine production levels compared to existing single-chain CAR-T therapies.

Notably, SynKIR-110 demonstrated approximately 10-fold lower interferon gamma (IFN-γ) levels and about 30-fold lower tumor necrosis factor alpha (TNFα) and interleukin-2 (IL-2) levels compared to CD28-based single-chain CAR-T therapies.

CD8 T cells that infiltrated tumor tissue treated with SynKIR-110 exhibited reduced expression of exhaustion-related markers TIM3, LAG3, and PD1 compared to the control group.

Furthermore, while the conventional single-chain CAR-T group showed off-target activity in vitro and CAR-T cell accumulation in normal lung tissue, these issues were not observed in the SynKIR-110 treatment group.

Dr. Laura Johnson, Verismo's Chief Scientific Officer (CSO) and Chief Operating Officer (COO), stated that these preclinical comparison results provide strong mechanistic evidence that the multi-chain KIR-CAR platform can maintain robust anti-tumor activity while mitigating the sustained signaling and non-specific off-target effects often associated with existing single-chain CAR-T therapies.

SynKIR-110 is currently in a Phase 1 clinical trial targeting advanced mesothelin-expressing solid tumors, including mesothelioma, ovarian cancer, and cholangiocarcinoma. The trial is in the dose escalation phase to determine the recommended Phase 2 dose (RP2D).

Preliminary clinical data presented at the American Association for Cancer Research (AACR 2026) annual meeting in May showed tumor reduction in nine patients across the first three dose escalation cohorts. Importantly, no dose-limiting toxicities (DLT) or grade 3 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed.

HLB Innovation's U.S. subsidiary, Verismo Therapeutics, has reported promising preclinical …

Revolutionary SynKIR-110 CAR-T Therapy: How It Outperforms Traditional Treatments in Cancer Control